Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

9.410 +1.980 (+26.65%)
Streaming Delayed Price Updated: 1:55 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 32,295,051
Open 9.835
Bid (Size) 9.400 (100)
Ask (Size) 9.410 (200)
Prev. Close 7.430
Today's Range 8.950 - 10.29
52wk Range 4.155 - 9.840
Shares Outstanding 133,976,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tuesday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill

Performance

YTD
+58.4%
+58.4%
1 Month
+26.3%
+26.3%
3 Month
+53.8%
+53.8%
6 Month
+114.8%
+114.8%
1 Year
-0.6%
-0.6%

More News

Read More
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
News headline image
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗
Via Stocktwits
Vir Biotechnology Inc (NASDAQ:VIR) Reports Q4 2025 Revenue Beat and Major Pipeline Updates ↗
Via Chartmill
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? ↗
Via Stocktwits
Topics Earnings
News headline image
Vir Biotechnology (VIR) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
Via The Motley Fool
News headline image
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
Via Benzinga

Frequently Asked Questions

Is Vir Biotechnology, Inc. - Common Stock publicly traded?
Yes, Vir Biotechnology, Inc. - Common Stock is publicly traded.
What exchange does Vir Biotechnology, Inc. - Common Stock trade on?
Vir Biotechnology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vir Biotechnology, Inc. - Common Stock?
The ticker symbol for Vir Biotechnology, Inc. - Common Stock is VIR on the Nasdaq Stock Market
What is the current price of Vir Biotechnology, Inc. - Common Stock?
The current price of Vir Biotechnology, Inc. - Common Stock is 9.410
When was Vir Biotechnology, Inc. - Common Stock last traded?
The last trade of Vir Biotechnology, Inc. - Common Stock was at 02/24/26 01:55 PM ET
What is the market capitalization of Vir Biotechnology, Inc. - Common Stock?
The market capitalization of Vir Biotechnology, Inc. - Common Stock is 1.26B
How many shares of Vir Biotechnology, Inc. - Common Stock are outstanding?
Vir Biotechnology, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.